Loading data for BOLD — first visit, this takes a few seconds.

알림

Boundless Bio Inc. (BOLD)

NasdaqGS: BOLD · 실시간 가격 · USD

2.86

+0.00 (0.00%)

종가 기준: Aug 19, 2026, 8:00 PM

2.85

-0.35%

애프터마켓: 4:57 PM

0.00% (1D)

데이터 없음

매수호가	2.05
시가총액	65.06M
매출 (ttm)	n/a
순이익 (ttm)	-64.01M
베타	0.38
EPS (ttm)	-2.85
P/E (ttm)	n/a
선행 P/E	-2.92
P/B (ttm)	0.97
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	2.84
거래량	95,547
평균 거래량 (20일)	1,289,464
시가	2.89
전일 종가	2.86
일중 범위	2.80 - 2.94
52주 범위	0.96 - 2.97
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BOLD 소개

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 28, 2024

직원 수 28

상장 거래소 NasdaqGS

티커 BOLD

웹사이트 https://boundlessbio.com

전체 기업 정보

재무 실적

2025년 Boundless Bio의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -58.2M로, -10.96% 감소했습니다.

재무제표

어닝 서프라이즈

Boundless Bio가 Aug 7, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -1.06 예상치 하회 -0.48, 및 -51.43% 전년 대비 감소.

뉴스

1개월 전 · Stocktwits

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today

Investors showed interest in businesses tied to artificial intelligence infrastructure, advanced biotechnology, and quantum computing.

1개월 전 · MT Newswires

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St

1개월 전 · MT Newswires

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State S

1개월 전 · Stocktwits

BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History

Boundless Bio is set to merge with Serapha Bio, with the transaction set to close in the fourth quarter of 2026.

6개월 전 · Zacks

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why

Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 페이지 중 1

Boundless Bio Inc. (BOLD)